Fig. 7. The antiviral activity of TMPyP4 is more potent than remdesivir in SARS-CoV-2-infected hamster.

a Schematic of SARS-CoV-2-infected hamster model. Hamsters infected with SARS-CoV-2 (10⁵ TCID₅₀ virus/hamster) were treated with vehicle (n = 5), 15 mg/kg TMPyP4 (n = 5), 15 mg/kg TMPyP2 (n = 5), 15 mg/kg remdesivir (n = 5) and 15 mg/kg remdesivir combined with 15 mg/kg TMPyP4 (n = 5) for consecutive 3 days, with the first dose given at 1 h before infection with SARS-CoV-2. b, c Viral RNA copies (b) and viral titers (c) in the hamster nasal wash, nasal turbinate and lung tissues of the indicated groups, determined by qRT-PCR and TCID₅₀ at day 3 after infection. Data are shown as means ± SEM, two-tailed Student’s t-test. n.s. not significant. ^*P < 0.05, ^***P < 0.001, ^****P < 0.0001.